[Skip to Content]
[Skip to Content Landing]
April 15, 1974


JAMA. 1974;228(3):288-289. doi:10.1001/jama.1974.03230280016014

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  The letter by Archer and Kosman (227:201, 1974) on the cardiologic uses of propranolol is enough to quicken the pulse of any physician and also make his heart skip a beat or two. What they—writing on behalf of the American Medical Association—have to say about propranolol's uses in cardiology makes for explosive as well as edifying reading; for their statements vis-à-vis Food and Drug Administration (FDA) controls come as a bombshell:Yet, some physicians still believe that the FDA has some legal authority to regulate the use of drugs that are on the market. This is incorrect... the physician... need not deny a patient medically sound treatment merely because a package insert does not include a specific indication, dosage, or other condition of use... The medical profession must never permit package inserts to be the final arbiter.The fact is that most physicians have been conditioned to